Patients in group III had lower prevalence of hypertension, total vein bypass grafting, CK-MB peak occurrence within 24 h, CK-MB peak value > 32.00 mg/l and lower serum creatinine, higher Ccr, shorter operation time, less venous grafts, lower CK-MB and cTnT peak values, and lower mid-term mortality compared with group IV (Table 4). The gene discussed is TNNT2; the disease is hypertensive disorder.